Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nexletol
Pharma
Esperion to go private in potential $1.1B buyout by ArchiMed
After a March M&A move of its own, Esperion Therapeutics is itself being acquired and taken private by healthcare investment firm ArchiMed.
Fraiser Kansteiner
May 1, 2026 11:26am
Esperion campaign sheds light on ‘Lipid Lurkers’ in artery walls
Jul 16, 2024 8:00am
Esperion, Daiichi resolve dispute with $125M settlement
Jan 3, 2024 1:22pm
Esperion hits Nexletol partner Daiichi with lawsuit
Mar 28, 2023 11:27am
Sun, Eisai, AstraZeneca—Fierce Pharma Asia
Mar 17, 2023 8:00am
Daiichi hesitant to fork over milestones to Esperion: filing
Mar 16, 2023 3:30pm
